Thu, May 15, 8:14 PM (37 days ago)
**Aptevo Therapeutics Inc. (APVO) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** Not explicitly stated, likely minimal as the company is in the clinical stage. - **Net Loss:** $6.4 million, slightly improved from $6.8 million in Q1 2024. - **Cash Flow:** Negative $6.6 million, primarily due to net loss and changes in working capital. - **Cash & Equivalents:** $2.1 million, significantly reduced from $8.7 million in Q1 2024. **Profit Margins:** - **Operating Margin:** Negative, reflecting ongoing losses. - **Net Margin:** Negative, consistent with the net loss reported. **Earnings Changes:** - **Earnings per Share (EPS):** Negative $4.39, improved from negative $368.21 in Q1 2024 due to reverse stock splits. **Quarterly Performance:** - **Operating Expenses:** $6.5 million, slightly decreased from $6.9 million in Q1 2024. - **Research & Development:** $3.6 million, decreased from $3.8 million in Q1 2024. - **General & Administrative:** $2.8 million, decreased from $3.2 million in Q1 2024. **Trends & Uncertainties:** - **Funding:** Company faces substantial doubt about continuing as a going concern, requiring additional capital. - **Clinical Trials:** Ongoing trials for mipletamig and ALG.APV-527, with positive early results. - **Market Risks:** Volatile stock price, dependence on regulatory approvals, and competitive landscape. **Future Operations Impact:** - **Capital Raising:** Plans to raise additional funds through equity issuances and strategic transactions. - **Operational Challenges:** Dependence on third-party manufacturers and collaborators, regulatory hurdles, and market competition. - **Financial Strategy:** Focus on cost reduction, strategic partnerships, and potential asset sales. **Key Takeaways:** - Aptevo Therapeutics is in a critical phase, requiring significant capital to advance clinical trials and secure regulatory approvals. - The company's financial health is precarious, with ongoing losses and reduced cash reserves. - Strategic initiatives include raising capital, managing operational costs, and navigating regulatory and competitive challenges.